Skip to content
  • News
  • Contact us
  • Careers
  •  
    • Kedrion Corporate
    • Kedrion S.P.A
    • Kedrion Biopharma GmbH
    • Kedrion Biopharma – Austria
    • Kedrion Biopharma – Portugal
    • Kedrion Biopharma – Poland
    • Kedrion Biopharma – Switzerland
    • Kedrion Biopharma – Russia
    • HUMAN Bioplazma Kft
    • Kedrion Mexicana S.A.
    • Kedrion de Colombia
    • Kedrion Betaphar
    • KEDPLASMA USA
    • RhoGAM
    • Koate
    • Gammaked
    • Albuked
    • KEDRAB
  •  
  •   
    • Linkedin
  • Kedrion Betaphar
  • About us
    • Corporate Structure
    • Annual Report
    • Corporate Social Responsibility
      • Environment, Health & Safety
      • Supporting our people
      • Support to communities
  • Expertise
    • Activities
    • Medical & Scientific Information
    • Product Development
    • Quality & Safety
  • Therapies
    • Therapeutic areas
      • Hematology/Hemophilia
      • Immunology/Neurology
      • Critical care
    • Business Partners
  • Services
    • Italian partnership
    • Contract manufacturing
    • Technology transfer
    • Biological Safety Center
  • Donors
    • Plasma
  • Pharmacovigilance
Find in Kedrion

NEWS


  • CORPORATE
  • EVENTS

The Fifth John Gorman Lectureship at the “Birth 2022 Congress”

Jan 09, 2023 |

These Conferences in Transfusion Medicine are made possible thanks to the unconditional support of Kedrion Biopharma

Permira Funds and the Marcucci family complete investment in Kedrion & BPL

Sep 02, 2022 |

Announced appointment of Ugo Di Francesco as CEO

Kedrion Biopharma Recognized for Innovation in Treating Rare Disease

Jun 28, 2022 |

RYPLAZIM® is the first FDA Approved Treatment for Plasminogen Deficiency Type 1

Kedrion Biopharma Extends Contract Manufacturing Agreement (CMA) for GAMMAKED in the US, Ensuring Availability to Patients

Feb 17, 2022 | CORPORATE

Kedrion Biopharma will continue to market and distribute GAMMAKED in the U.S. through end of 2025

Kedrion Biopharma to commercialize RYPLAZIM® in U.S

Dec 02, 2021 | CORPORATE

RYPLAZIM® (plasminogen, human-tvmh) will address needs in patients with ultra-rare condition Plasminogen Deficiency Type 1

Kedrion grows in North America as it completes acquisition of Prometic

Oct 18, 2021 |

Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency

Kedrion stronger in North America and further committed to rare diseases

Jul 19, 2021 | CORPORATE

Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update

Jun 04, 2021 | CORPORATE

KEDRAB® is now the first and only HRIG available in the U.S. to be clinically studied in children

First patient enrolled in KIDCARES10

Apr 01, 2021 | CORPORATE

Kedrion Biopharma Pediatric Primary Immunodeficiency Study

Kedrion Biopharma Phase III Trial, CARES10, achieves important milestone

Jan 04, 2021 | CORPORATE

Kedrion Biopharma, an international biopharmaceutical company specialized in the manufacture and distribution of plasma-derived therapeutic products used in treating rare and serious diseases.

Posts navigation

1 2 3 … 5 Next

Kedrion

Kedrion Biopharma Inc.
All rights reserved.
Dec 2019 CO-0109-11-2019
INTENDED FOR US AUDIENCES ONLY

INFORMATION

  • Privacy Statement
  • Privacy Policy
  • Terms of Use
  • Site map

HIGHLIGHTS

  • Annual Declaration of Compliance for the State of California
  • Code of Ethics and Code of Conduct

Where We Are

© 2023 Kedrion Biopharma Inc.

You are now leaving www.kedrion.us Medical information including licensed uses may be different outside of USA. Are you sure?

Kedrion usLogo Header Menu
    • About us
      • Corporate Structure
      • Annual Report
      • Corporate Social Responsibility
        • Environment, Health & Safety
        • Supporting our people
        • Support to communities
    • Expertise
      • Activities
      • Medical & Scientific Information
      • Product Development
      • Quality & Safety
    • Therapies
      • Therapeutic areas
        • Hematology/Hemophilia
        • Immunology/Neurology
        • Critical care
      • Business Partners
    • Services
      • Italian partnership
      • Contract manufacturing
      • Technology transfer
      • Biological Safety Center
    • Donors
      • Plasma
    • Pharmacovigilance
  • News
  • Contact Us
  • Careers
  • Kedrion’s Sites
    • Kedrion Corporate
    • Kedrion S.p.A
    • Kedrion Biopharma GmbH
    • Kedrion Biopharma – Austria
    • Kedrion Biopharma – Portugal
    • Kedrion Biopharma – Poland
    • Kedrion Biopharma – Switzerland
    • Kedrion Biopharma – Russia
    • HUMAN Bioplazma Kft
    • Kedrion Mexicana S.A.
    • Kedrion Betaphar
    • KEDPLASMA USA
    • RhoGAM
    • Koate
    • Gammaked
    • Albuked
    • KEDRAB
  • Social Network
    • Linkedin